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Abstract
We explored predictive factors of pseudoprogression (PsP) and its impact on 
prognosis in a retrospective series of uniformly treated glioblastoma patients. 
Patients were classified as having PsP, early progression (eP) or neither (nP). 
We examined potential associations with clinical, molecular, and basal imaging 
characteristics and compared overall survival (OS), progression- free survival 
(PFS), post- progression survival (PPS) as well as the relationship between PFS 
and PPS in the three groups. Of the 256 patients studied, 56 (21.9%) were 
classified as PsP, 70 (27.3%) as eP, and 130 (50.8%) as nP. Only MGMT 
methylation status was associated to PsP. MGMT methylated patients had a 
3.5- fold greater possibility of having PsP than eP (OR: 3.48; 95% CI: 1.606–7.564; 
P = 0.002). OS was longer for PsP than eP patients (18.9 vs. 12.3 months; 
P = 0.0001) but was similar for PsP and nP patients (P = 0.91). OS was 
shorter–though not significantly so—for PsP than nP patients (OS: 19.5 vs. 
27.9 months; P = 0.63) in methylated patients. PPS was similar for patients 
having PsP, eP or nP (PPS: 7.2 vs. 5.4 vs. 6.7; P = 0.43). Neurological deterio-
ration occurred in 64.3% of cases at the time they were classified as PsP and 
in 72.8% of cases of eP (P = 0.14). PsP confounds the evaluation of disease 
and does not confer a survival advantage in glioblastoma.
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Introduction
Standard first- line treatment for newly diagnosed glioblas-
toma is surgery followed by radiotherapy with concomitant 
and adjuvant temozolomide [1]. Pseudoprogression (PsP) 
is a transient magnetic resonance imaging (MRI) pattern 
mimicking tumor progression but not necessarily accom-
panied by clinical deterioration. It occurs most frequently 
during the first 3 months after radiation therapy and 
improvement will usually occur within a few weeks or 
months. PsP is more frequent in patients treated with 
concomitant temozolomide than in those receiving radia-
tion therapy alone [2, 3] and is particularly frequent in 
patients with O6- methylguanine- DNA methyltransferase 
(MGMT) promoter methylation (MGMT_MET) [4, 5]. In 
spite of new and promising advanced MRI and PET- based 
techniques [6–13], PsP remains indistinguishable from early 
progression (eP). Since a final diagnosis can only be reached 
through histopathological verification or subsequent MRIs, 
PsP can confound treatment monitoring, with direct con-
sequences in clinical practice, as it can lead to prematurely 
withholding adjuvant temozolomide or to overestimating 
the efficacy of a second- line therapy. It is thus recom-
mended to continue with adjuvant temozolomide for at 
least 3 months after concomitant therapy regardless of 
findings on the first post- radiation evaluation. However, 
some patients experience neurological decline that precludes 
maintaining adjuvant temozolomide, while patients with 
true eP need to wait until the following evaluation instead 
of being switched immediately to another, potentially effec-
tive, treatment [2, 14].
There is thus a clear need for imaging, clinical or 
molecular markers to discriminate PsP from eP. In this 
study, we retrospectively examined pre- treatment predic-
tive factors of PsP among glioblastoma patients. In addi-
tion, we examined the potential impact of PsP on outcome 
and compared progression- free survival (PFS), post- 
progression survival (PPS) and overall survival (OS) in 
patients with PsP, eP, or neither (nP).
Methods
Patients
Figure 1 shows the flow of patients through the study. 
Between July 2004 and April 2015, the GLIOCAT project 
recruited 432 consecutive patients with glioblastoma from 
six institutions, all of whom had received the standard 
first- line treatment. All patients were reviewed histologi-
cally to confirm the presence of astrocytic tumor with 
microvascular proliferation and/or necrosis. The 256 
patients who had completed the concurrent treatment with 
radiotherapy and temozolomide and who had had their 
first MRI evaluation within 2 months after the completion 
of radiotherapy were selected for this retrospective sub-
study. This study was approved by the Ethics Committees 
of all the participating institutions. The investigators 
obtained informed consent of each participant or each 
participant’s guardian to be included in the project.
Disease progression was defined as MRI progression 
and/or clinical deterioration that led to stopping the 
planned first- line therapy and changing to either best 
supportive care or second- line therapy. Patients were clas-
sified in three groups: PsP, eP, or nP. Those who were 
diagnosed as having suspected progressive disease at their 
first evaluation but whose subsequent MRI evaluations 
(performed after the third and sixth cycle of adjuvant 
temozolomide) showed stable disease or partial or complete 
response were classified as PsP. Those whose first MRI 
evaluation showed a pattern indicating suspected progres-
sive disease that was confirmed at subsequent evaluations 
were classified as eP. Those with progressive disease at 
the first evaluation, even if based only on neurological 
deterioration, but who stopped adjuvant temozolomide 
were also classified as eP. Finally, those whose first evalu-
ation showed stable disease or partial or complete response 
and who continued treatment with adjuvant temozolomide 
with no worsening of disease at subsequent evaluations 
while on this treatment were classified as nP. After the 
first MRI evaluation, subsequent MRIs were performed 
after the third and sixth cycle of temozolomide.
The date of progression was the date of the first pro-
gression if subsequent MRI evaluations showed no 
improvement.
Baseline clinical, molecular, and imaging 
data
MGMT_MET was assessed by methylation- specific PCR 
and isocitrate dehydrogenase 1 (IDH1) mutations by 
immunohistochemistry. Information was obtained on the 
date of progression, treatment after progression, and date 
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of death or last control. Tumor imaging characteristics 
(size, location and eloquence)[15] were evaluated on axial 
sections on pre- surgical MRIs that were available to all 
radiologists through a shared platform. (See Table 1 for 
explanation.)
Statistical analyses
Categorical variables were compared with the χ2 or Fisher’s 
exact test. PFS was defined as the time from surgery to 
documented disease progression or death from any cause. 
PPS was defined as the time from confirmed progression 
to the last visit or death. OS was defined as the time 
from surgery to death from any cause. Patients who were 
still progression- free or alive at the date of last contact 
were censored. Median PFS, PPS and OS were calculated 
with the Kaplan–Meier method and compared using the 
log- rank test. The Cox proportional hazards model was 
used to calculate hazard ratios (HRs) with their 95% 
confidence intervals (CIs). The non- parametric Kruskall–
Wallis test or the Mann–Whitney U test, as appropriate, 
was used to compare the PFS- PPS relationship among 
the patient groups. All statistical tests were two- sided and 
significance was set at 0.05. All analyses were performed 
with SPSS v24.0 (IBM).
Literature search criteria
We performed an NCBI Pubmed search for articles pub-
lished in English before March 2017 to identify publica-
tions on Pseudoprogression or Radionecrosis. Using the 
key words “pseudoprogression AND glioblastoma’’ and 
“radionecrosis AND glioblastoma’’, we had 770 and 220 
hits, respectively. We then selected publications reporting 
data on patients and reviews that focused on “imaging”, 
“MGMT”, “IDH mutations”, “surgery”, “clinical charac-
teristics”, “clinical outcome”, and “differential diagnosis”. 
Finally, we selected 130 publications for review and cited 
the ones most relevant to our study in our 
manuscript.
Results
Patient characteristics are shown in Table 1. Fifty- six 
patients (21.9%) were classified as PsP, 70 (27.3%) as 
eP, and 130 (50.8%) as nP (Fig. 1).
Figure 1. Consort diagram showing flow of patients through the study. SD, stable disease; PR, partial response; CR, complete response; PD, progressive 
disease; PsP, pseudoprogression; eP, early progression; nP, neither pseudoprogression nor early progression.
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Table 1. Characteristics of patients according to clinical factors and subgroup (PsP vs. eP vs. nP).
Characteristic
All patients 
N = 256 
N (%)
PsP 
N = 56 
N (%)
eP 
N = 70 
N (%)
nP 
N = 130 
N (%) P1
Age, years 0.59
Median (range) 61 (23–80) 59 (28–77) 62 (40–79) 61 (23–80)
<50 51 (19.9) 12 (21.4) 11 (17.5) 28 (21.5)
≥50 205 (80.1) 44 (78.6) 59 (84.3) 102 (78.5)
Gender 0.37
Male 157 (61.3) 33 (58.9) 39 (55.7) 85 (65.4)
Female 99 (38.7) 23 (41.4) 31 (44.3) 45 (34.6)
KPS 0.52
70–100 191 (74.6) 40 (71.4) 50 (71.4) 101 (77.7)
<70 65 (25.4) 16 (28.6) 20 (28.6) 29 (22.3)
Anticonvulsant drugs 0.55
No 136 (53.1) 28 (50.0) 41 (58.6) 67 (51.5)
Yes 120 (46.9) 28 (50.0) 29 (41.4) 63 (48.5)
Type of surgery 0.06
Complete resection 36 (14.1) 5 (8.9) 5 (7.1) 26 (20.0)
Partial resection 192 (75.0) 46 (82.1) 58 (82.9) 88 (67.7)
Biopsy only 28 (10.9) 5 (8.9) 7 (10.0) 16 (12.3)
Post–op therapy
Received 60 Gy 253 (98.8) 54 (96.4) 69 (98.6) 130 (100) 0.11
Completed concurrent TMZ 243 (94.9) 54 (96.4) 64 (91.4) 125 (96.2) 0.24
Median no. TMZ cycles (range) 5 (1–20) 6 (2–20) 2 (1–5) 6 (1–12) –
MGMT methylation2 (N = 221) (N = 50) (N = 66) (N = 105) 0.005
Methylated 109 (49.3) 34 (68.0) 25 (37.9) 50 (47.6)
Unmethylated 112 (50.7) 16 (32.0) 41 (62.1) 55 (52.4)
IDH1 mutations2 (N = 162) (N = 38) (N = 49) (N = 75) 0.09
Detected 9 (5.5) 2 (5.3) 0 (0) 7 (9.3)
Not detected 153 (94.5) 36 (94.7) 49 (100) 68 (90.7)
MMSE score (N = 135) (N = 32) (N = 27) (N = 76)
<27 49 (19.1) 15 (46.9) 10 (37.0) 24 (31.6)
≥27 86 (33.6) 17 (53.1) 17 (63.0) 52 (68.4) 0.32
Dexamethasone dose at start of 
concurrent therapy
(N = 234) (N = 53) (N = 63) (N = 118) 0.01
≤2 mg 63 (26.9) 10 (18.9) 11 (17.5) 42 (35.6)
>2 mg 171 (73.1) 43 (81.1) 52 (82.5) 76 (64.4)
Dexamethasone stopped during concurrent therapy 0.60
No 222 (86.7) 50 (89.3) 62 (88.6) 110 (84.6)
Yes 34 (13.3) 6 (10.7) 8 (11.4) 20 (15.4)
Tumor size T1 Gd3 (N = 194)3 (N = 41)3 (N = 49)3 (N = 104)3 0.30
≤5 cm 103 (53.1) 25 (61.0) 28 (57.1) 50 (48.1)
>5 cm 91 (46.9) 16 (39.0) 21 (42.9) 54 (51.9)
Tumor size T2 Flair3 (N = 185)3 (N = 39)3 (N = 46)3 (N = 103) 3 0.91
≤5 cm 32 (17.3) 7 (17.9) 7 (15.2) 18 (18.0)
>5 cm 153 (82.7) 32 (82.1) 39 (84.8) 85 (82.0)
Tumor location T1 Gd3 (N = 194)3 (N = 41)3 (N = 49)3 (N = 104)3 0.11
Group A 103 (53.1) 18 (43.9) 22 (44.9) 63 (60.6)
Group B 72 (37.1) 17 (41.5) 24 (49.0) 31 (29.8)
Group C 19 (9.8) 6 (14.6) 3 (61.1) 10 (9.6)
Tumor location T2 Flair3 (N = 184)3 (N = 40)3 (N = 56)3 (N = 98)3 0.35
Group A 87 (47.3) 17 (42.5) 17 (37.0) 53 (54.1)
Group B 65 (35.3) 16 (40.0) 20 (43.5) 29 (29.6)
Group C 32 (17.4) 7 (17.5) 9 (19.6) 16 (16.3)
Eloquence T1 Gd3 (N = 193)3 (N = 41)3 (N = 48)3 (N = 104)3 0.16
No 138 (71.5) 28 (68.3) 30 (62.5) 80 (76.9)
Yes 55 (28.5) 13 (31.7) 18 (37.5) 24 (23.1)
(continues)
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There were significant differences in MGMT_MET 
status among the three patient groups (P = 0.005), 
between PsP and eP patients (P = 0.001), and between 
PsP and nP patients (P = 0.02). Patients with MGMT_
MET had a 3.5- fold greater possibility of having PsP 
rather than eP (odds ratio [OR]: 3.48; 95% CI: 1.606–
7.564; P = 0.002).
Significant differences in dexamethasone dose (P = 0.01) 
and a trend toward differences in type of surgery (P = 0.06) 
and in IDH1 mutation status (P = 0.09) were also observed 
among the three patient groups. There were no differences 
among the three patient groups of patients in tumor size, 
tumor location or the eloquence of adjacent brain, as 
measured by T1 Gd or T2 Flair sequences (details in 
Table 1).
Overall survival
With a median follow- up of 17.0 months (range: 10.7–24.5), 
age ≤50 years, complete resection, MGMT_MET, and IDH1 
mutations were associated with longer OS. Patients with 
eP had shorter OS (12.3 months) than those with PsP 
(18.9 months) or nP (19.7 months) (P < 0.001). There 
were no significant differences between those with PsP 
and those with nP (P = 0.91).
Among patients with MGMT_MET, those with nP had 
longer OS than those with PsP, although this difference 
was not significant (27.9 vs. 19.5 months). Among patients 
without MGMT_MET, OS was similar for patients with 
PsP and those with nP (17.9 vs. 17.5 months) (Table S1).
Post- progression treatment and PPS
At the time of analysis, 245 patients had relapsed after 
first- line treatment. Treatments at relapse, including hos-
pice care, were similar across the three patient subgroups. 
Neurological deterioration—either alone or with MRI 
progression—occurred in 64.3% of cases at the time they 
were classified as PsP and in 72.8% of cases of eP, while 
imaging progression with no neurological deterioration 
was observed in 30.4% of patients with PsP and in 22.9% 
of those with eP (P = 0.02) (Table S2).
After progression, PPS was similar for all patients what-
ever response to first- line therapy (P = 0.43) or methyla-
tion status were (P = 0.35) (Figure S1). Among patients 
with MGMT_MET, PPS was 7.9 months for those with 
PsP, 3.1 months for those with eP, and 7.3 months for 
those with nP (P = 0.17). PsP was not better than nP 
regarding PFS (P = 0.81) or PPS (P = 0.92) even when 
analyzed by MGMT status (Table 2).
Some patients classified as eP had long PPS after second- 
line therapy (Fig. 2A–C). Though it seemed logical to 
hypothesize that patients with shorter PFS would also have 
shorter PPS, this was not always the case. Differences in 
this pattern were significant when comparing PsP versus 
eP versus nP (P = 0.009), PsP versus eP (P = 0.01), and 
eP versus nP (P = 0.006), but not when comparing PsP 
and nP. Among patients without MGMT_MET, these dif-
ferences were maintained to a certain extent for eP versus 
nP (P = 0.04) but not in other cases. Among patients 
with MGMT_MET, there were no differences between 
patients classified as eP and those classified as PsP or nP.
Characteristic
All patients 
N = 256 
N (%)
PsP 
N = 56 
N (%)
eP 
N = 70 
N (%)
nP 
N = 130 
N (%) P1
Eloquence T2 Flair3 (N = 188)3 (N = 40)3 (N = 47)3 (N = 101)3 0.11
No 124 (66.0) 25 (62.5) 26 (55.3) 73 (72.3)
Yes 64 (34.0) 15 (37.5) 21 (44.7) 28 (27.7)
PsP, pseudoprogression; eP, early progression; nP, neither pseudoprogression nor early progression; KPS, Karnofsky performance status; TMZ, temo-
zolomide; MMSE, Mini Mental State Examination. Percentages are given over the number of patients with available data. 
1P- values are given for comparison of the distribution of variables in the three subgroups of patients (PsP vs. eP v.s nP). The analyses comparing the 
distribution of variables between PsP and eP showed no significant differences between the groups except for MGMT methylation (P = 0.001). 
2Among the 109 patients with MGMT methylation, 34 (31.2%) were classified as PsP, 25 (22.9%) as eP, and 50 (45.9%) as nP. Of the 112 patients 
without MGMT methylation, 16 (14.3%) were classified as PsP, 41 (36.6%) as eP, and 55 (52.4%) as nP. Among patients with PsP, 68% had MGMT 
methylation. Five patients were secondary GBM and had had previous surgery for low- grade glioma. Only two of these patients had IDH1- mutated 
tumors. Seven patients had IDH1- mutated tumors without evidence of a previous diagnosis of a lower grade glioma. 
3Tumor size was measured on T1 enhanced sequences and on T2 Flair images. In the case of multiple enhanced lesions, the sum of the greatest di-
ameters was estimated as a variable. Location was evaluated in three groups: group A tumors were located in the right cerebral hemisphere or left 
occipital lobe; group B tumors were located in the left frontal, parietal or temporal lobe; and group C tumors were located mainly in or partly extend-
ing to the thalamus, caudate nucleus and/or internal capsule. Tumors partly extending to the structures medial to the internal capsule, even if located 
mainly outside the midline structures, were classified as group C, together with other deep- seated tumors and were considered as eloquent areas. 
Tumors in eloquent brain areas were those located in the sensorimotor cortex, language cortex, internal capsule, thalamus, corpus callosum, fornix, 
hypothalamus, and brain stem.
Table 1. (continued)
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Discussion
We have reviewed our series of patients in order to identify 
predictive factors for PsP and found that MGMT_MET 
patients had a 3.5- fold greater possibility of having PsP 
than eP. In consistent with previous reports [4, 5, 16, 17], 
none of the IDH1- mutated patients had eP (see Table 1)
and patients undergoing gross total resection showed a 
trend toward a lower probability of having either PsP or 
eP. To the best of our knowledge, this is the first study 
to examine the potential association between imaging base-
line tumor characteristics (size, location or eloquence) and 
PsP. However, none of these characteristics was associated 
with either PsP or eP (Table 1).
Previous studies have reported PsP in 12- 50% of patients 
[18–21] although when applying only strict MRI imaging 
criteria, the incidence can be as low as 11.4% [22]. 
Neurological decline accompanied PsP in 64.3% of our 
patients and was not useful for distinguishing PsP and 
eP. Since neurological decline takes months to stabilize 
and may preclude continuing with temozolomide, it is 
likely a major reason for the high interest in PsP [23].
Our findings on outcome confirm previous reports [4, 
19, 20, 23] that patients with PsP have longer OS than 
those with eP but not than those with nP.
Confounding factors in the evaluation of progression 
are PsP, late PsP and radionecrosis. Although radionecrosis 
is considered a late adverse event [24, 25], it can also 
overlap in time with PsP. PsP has been observed later 
than the first 3 months post- radiotherapy [10, 18, 22, 
26] and radionecrosis has been found in surgical specimens 
immediately after radiotherapy [27, 28]. Radionecrosis is 
pathologically defined [24] and a mixed pattern of viable 
tumor and radionecrosis can be found in PsP [29, 30]. 
Clinically, both PsP and radionecrosis can be accompanied 
by cognitive and neurological decline that can stabilize 
or reverse [2, 4, 23, 31]. The primary risk factor for 
radionecrosis is total radiation dose, fraction size and 
irradiated volume; it rarely appears at doses lower than 
50 Gy and standard fractions of 1.8–2.0 Gy [30, 32]. 
Chemotherapy increases the risk of both radionecrosis 
and PsP [25]. The higher incidence of PsP in patients 
with MGMT_MET could be explained by the rationale 
for combining temozolomide with radiotherapy, based on 
Table 2. Progression- free survival and post- progression survival.
N PFS (mo) 95% CI P N PPS (mo) 95% CI P
All patients 256 8.5 8.1–9.0 245 6.7 5.4–8.1
PsP vs. all other patients 0.01 0.78
PsP 56 10.5 10.0–11.1 53 7.2 5.2–9.2
eP + nP 200 7.8 7.2–8.5 192 6.7 4.9–8.6
PsP vs. nP 0.81 0.92
PsP 56 10.5 10.0–11.1 53 7.2 5.2–9.2
nP 130 10.4 9.0–11.8 122 6.7 5.0–8.6
PsP vs. eP vs. nP 0.0001 0.43
PsP 56 10.5 10.0–11.1 53 7.2 5.2–9.2
eP 70 5.3 5.0–5.7 70 5.4 1.0–9.9
nP 130 10.4 9.0–11.8 122 6.7 5.0–8.6
MGMT status 0.0001 0.35
Methylated 109 8.8 7.3–10.3 101 6.7 5.0–8.5
Unmethylated 112 8.2 7.4–9.0 109 7.0 4.7–9.3
Subanalysis among patients with MGMT methylation
PsP vs. nP 0.35 0.96
PsP 34 10.3 6.9–13.7 33 7.9 6.0–9.9
nP 50 13.9 8.8–19.0 43 7.3 4.4–10.2
PsP vs. eP vs. nP 0.0001 0.17
PsP 34 10.3 6.9–13.7 33 7.9 6.0–9.9
eP 25 5.5 5.0–6.1 25 3.1 0.8–5.6
nP 50 13.9 8.8–19.0 43 7.3 4.4–10.2
Subanalysis among patients without MGMT methylation
PsP vs. nP 0.23 0.67
PsP 16 10.5 10.1–11.0 14 6.4 1.2–11.7
nP 55 9.7 7.9–11.5 54 6.8 3.5–10.1
PsP vs. eP vs. nP 0.0001 0.71
PsP 16 10.5 10.1–11.0 14 6.4 1.2–11.7
eP 41 5.5 4.9–6.1 41 7.8 4.3–11.4
nP 55 9.7 7.9–11.5 54 6.8 3.5–10.1
PPS, post- progression survival; PsP, pseudoprogression; PFS, progression- free survival
2864 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
C. Balaña et al.Pseudoprogression Adverse Event in GB
preclinical data suggesting additive or synergistic activity 
[33].
A limitation of the study is that our findings are based 
on retrospective data not subjected to a pre- specified 
periodicity of disease evaluations. The only prospective 
study published in 2008 did not compare post- progression 
outcomes and did not take into account late PsP or radi-
onecrosis as confounding factors [4]. Our study brings 
up the current existing dilemma when evaluating the 
disease: some of our patients classified as eP who had 
relatively long PPS on second- line therapy could well have 
had a PsP, and those who progressed later than 3 months 
post- radiotherapy could well have had late PsP or radi-
onecrosis [10, 22, 26] since no pathological diagnosis was 
obtained. All these confounding factors may explain the 
difference in the patterns shown in Figure 2, especially 
considering the limited efficacy of treatments for recurrent 
disease.
According to our results, PsP (and radionecrosis) should 
be considered confounding factors and undesired adverse 
events of concomitant therapy rather than indications of 
treatment efficacy. Consequently, we suggest they should 
be reported as such in clinical trials exploring alternative 
radiotherapy doses and fractions combined with chemo-
therapy [34–36]. Moreover, we could speculate that it 
would also be of interest to investigate a reduction in 
total radiation dose to reduce the risk of PsP especially 
in patients with MGMT_MET.
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